Purpose: To develop an adaptable gene-based vector that will confer immune cell specificity
to various cancer types. Experimental Design: Human and mouse T cells were genetically …

In an effort to broaden the applicability of adoptive cellular immunotherapy toward
nonmelanoma cancers, we have designed chimeric antibody/T-cell receptor genes …

Tumor-associated antigens are typically nonimmunogenic in cancer patients,“immune
surveillance” having manifestly failed. The fact that most tumor antigens are normal human …

Chimeric antigen receptor (CAR) gene-engineered T cell therapy holds the potential to
make a meaningful difference in the lives of patients with terminal cancers. For decades …

Engineering immune cells to target cancer is a rapidly advancing technology. The first
commercial products, chimeric-antigen receptor (CAR) T cells, are now approved for …

Adoptive immunotherapy using T lymphocytes genetically modified to express a chimeric
antigen receptor (CAR-T) holds considerable promise for the treatment of cancer. However …

Adoptive immunotherapies composed of T cells engineered to express a chimeric antigen
receptor (CAR) offer an attractive strategy for treatment of human cancer. However, CARs …

The ultimate goal of immunotherapy of cancer is to make use of the immune system of
patients to eliminate malignant cells. Research has mainly focused on the generation of …

Purpose: The adoptive transfer of lymphocytes genetically modified to express tumor
reactive T-cell receptors (TCR) can mediate tumor regression. Some tumor-infiltrating …

Oncology immunotherapy has been a significant advancement in cancer treatment and
involves harnessing and redirecting a patient's immune response towards their own tumour …